Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Curious about Monday at ASH, nothing noted about this
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5340)
•••
Comment by Noteableon Dec 12, 2021 3:05pm
199 Views
Post# 34223302

RE:Curious about Monday at ASH, nothing noted about this

RE:Curious about Monday at ASH, nothing noted about this Just for clarification - 'Reolysin' was the trade name given to ONCY's TD3 strain of reovirus for human adiministration, when Thompson was CEO, and is still used by many researchers to describe pelareorep. However, the generic name of the TD3 strain is 'pelareorep' and this generic name was granted by the FDA after this regulatory agency stated that the name 'Reolysin' was too similar in pronounciation to another yet entirely different drug on the market, and that in an effort to avoid any confusion between the two drugs,  the generic name of 'pelarerep' be used when referring to TD3 reovirus, rather than the earler given name 'Reolysin'.

Furthermore the poster entitled 3337 The Clinical Oncolytic Reovirus Formulation Reolysin Synergistically Augments the Anti-Leukemic Activity of Azacitidine will be presented at ASH on December 13, 2021.
 
 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities